<code id='3D920DD9DC'></code><style id='3D920DD9DC'></style>
    • <acronym id='3D920DD9DC'></acronym>
      <center id='3D920DD9DC'><center id='3D920DD9DC'><tfoot id='3D920DD9DC'></tfoot></center><abbr id='3D920DD9DC'><dir id='3D920DD9DC'><tfoot id='3D920DD9DC'></tfoot><noframes id='3D920DD9DC'>

    • <optgroup id='3D920DD9DC'><strike id='3D920DD9DC'><sup id='3D920DD9DC'></sup></strike><code id='3D920DD9DC'></code></optgroup>
        1. <b id='3D920DD9DC'><label id='3D920DD9DC'><select id='3D920DD9DC'><dt id='3D920DD9DC'><span id='3D920DD9DC'></span></dt></select></label></b><u id='3D920DD9DC'></u>
          <i id='3D920DD9DC'><strike id='3D920DD9DC'><tt id='3D920DD9DC'><pre id='3D920DD9DC'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:8445
          Cholesterol
          APStock

          Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

          Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed  reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

          advertisement

          The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more
          Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank
          Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

          WhatdoesCovid-19haveinstoreforthewinter?Whenaregooddatanotgoodenough?Andhowmanywould-beWegovysarethe